Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study. Read more about Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis. Read more about SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis.
Dietary Patterns in Prostate Cancer Prevention and Management: A Systematic Review of Prospective Cohort Studies and Randomized Clinical Trials. Read more about Dietary Patterns in Prostate Cancer Prevention and Management: A Systematic Review of Prospective Cohort Studies and Randomized Clinical Trials.
The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies. Read more about The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies.
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer. Read more about Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer.
Re: Rajal B. Shah, Gladell P. Paner, Liang Cheng, et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach. Eur Urol. 2025;88:8-10. Read more about Re: Rajal B. Shah, Gladell P. Paner, Liang Cheng, et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach. Eur Urol. 2025;88:8-10.
Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data. Read more about Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data.
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. Read more about Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer.
Prostate Cancer Active Surveillance Without Biopsy? Not Quite Yet, but Watch This Space. Read more about Prostate Cancer Active Surveillance Without Biopsy? Not Quite Yet, but Watch This Space.
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study. Read more about Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study.
